On 19 MAY NeoStem Inc (NASDAQ:NBS) announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. NeoStem Inc (NASDAQ:NBS) weekly performance is 14.29%. On last trading day company shares ended up $6.72. Analysts mean target price for the company is $20.60. NeoStem Inc (NASDAQ:NBS) distance from 50-day simple moving average (SMA50) is 3.80%.
On 12 MAY Verastem Inc (NASDAQ:VSTM) announced the appointment of Paul A. Friedman, M.D. to its Board of Directors. “We are delighted to welcome Paul to the Verastem Board of Directors,” said Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman. Verastem Inc (NASDAQ:VSTM) shares advanced 13.95% in last trading session and ended the day on $10.29. VSTM return on assets is -38.90%. Verastem Inc (NASDAQ:VSTM) quarterly performance is -29.52%.
On 21 MAY XenoPort, Inc. (NASDAQ:XNPT) announced that it has filed a presentation with the U.S. Securities and Exchange Commission (SEC) in connection with the Company’s upcoming Annual Meeting, which will be held on June 11, 2014. XenoPort, Inc. (NASDAQ:XNPT) shares moved up 8.02% in last trading session and was closed at $4.04, while trading in range of $3.74 – $4.07. XenoPort, Inc. (NASDAQ:XNPT) year to date (YTD) performance is -29.74%.
On 26 MAY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.15. The company had revenue of $8.30 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was down 55.4% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post $-2.02 EPS for the current fiscal year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ended the last trading day at $63.28. Company weekly volatility is calculated as 7.94% and price to cash ratio as 7.18. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) showed a positive weekly performance of 8.62%.
On 12 MAY Arrowhead Research Corp (NASDAQ:ARWR) targeted RNAi therapeutics in the United States. Currently there are 6 analysts that rate Arrowhead Research a buy, no analysts rate it a sell, and 1 rates it a hold. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is 9.55%. On last trading day company shares ended up $12.85. Analysts mean target price for the company is $27.90. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -10.49%.